Healthcare
Veracyte, Inc.(VCYT)
Live Price
Offline$49.15
+3.85% today
1Y Change
+84.01%
Window
Jun 23, 2025 โ Jun 15, 2026
- Market Cap
- $2.64B
- Revenue Growth
- +16.0%
- EPS Growth
- +162.5%
- Dividend Yield
- 0.0%
Coverage: 246 bars ยท Jun 23, 2025 โ Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Veracyte, Inc. (VCYT) is a Healthcare stock with a market cap of $2.64B and listed on NASDAQ. The stock last traded around $49.15 and up 84.0% across the available one-year price window (Jun 23, 2025 โ Jun 15, 2026). Baseline metrics include revenue growth of +16.0%, EPS growth of +162.5%, a dividend yield of 0.0%. What stands out right now is revenue +16.0%, EPS +162.5%, free cash flow +98.5% with operating margin 9.0% and ROIC 3.4%. Valuation already assumes a fairly strong business story at P/E 39.5 and price/sales 5.1. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines VCYT price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+16.0% vs +7.6% peer median
Operating Margin
Below sector median
+9.0% vs +19.4% peer median
P/E
Above sector median
39.5 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 6, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +16.0% and EPS at +162.5%, with operating margin around 9.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +4.2% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 6, 2026 | โ | -1.0% | -7.1% | +21.2% |
2026 Feb 25, 2026 | +29.8% | +8.5% | +1.5% | -8.2% |
2025 Nov 4, 2025 | +59.4% | +27.5% | +18.1% | +32.2% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
VCYT
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
VCYT Max Drawdown
-39.23%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for VCYT and SPY.
Company Overview
Veracyte, Inc.
NASDAQ Global Market
Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Genomic Sequencing Classifier and Percepta Nasal Swab Test for lung cancer diagnosis; Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis; and Immunoscore Colon Cancer test for colon cancer diagnosis. It is also developing Percepta Genomic Atlas to help inform lung cancer treatment decisions; Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. Veracyte, Inc. has technology licensing and collaboration arrangements with Johnson & Johnson; Acerta Pharma; and CareDx. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
- Leadership
- Marc A. Stapley
- IPO Date
- Oct 30, 2013
- Employees
- 824
- Street Address
- 6000 Shoreline Court
- Mailing
- South San Francisco, CA, 94080
- Region
- South San Francisco, CA, US
- Reporting Currency
- USD
- Investor Line
- 650 243 6300
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 39.5
- EV/EBITDA
- 27.8
- Price/Sales
- 5.1
- Price/Book
- 2.0
Growth
- Revenue
- +16.0%
- EPS
- +162.5%
- Free Cash Flow
- +98.5%
Profitability
- Gross Margin
- 70.6%
- Operating Margin
- 9.0%
- Net Margin
- 12.8%
- ROE
- 5.3%
- ROIC
- 3.4%
Balance Sheet
- Debt/Equity
- 0.03
- Current Ratio
- 8.15
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.